| Full text | |
| Author(s): |
Oliveira, Cleide
[1]
;
Valois, Mayara Vioto
[1]
;
Ottaiano, Tatiana Fontes
[1]
;
Miranda, Antonio
[2]
;
Hansen, Daiane
[1]
;
Sampaio, Misako Uemura
[1]
;
Vilela Oliva, Maria Luiza
[1]
;
de Abreu Maffei, Francisco Humberto
[3]
Total Authors: 8
|
| Affiliation: | [1] Univ Fed Sao Paulo, Dept Bioquim, Rua Tres Maio 100, BR-04044020 Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Dept Biofis, BR-04044020 Sao Paulo, SP - Brazil
[3] Univ Estadual Paulista, Dept Cirurgia Ortopedia, BR-18618970 Botucatu, SP - Brazil
Total Affiliations: 3
|
| Document type: | Journal article |
| Source: | SCIENTIFIC REPORTS; v. 11, n. 1 JUN 29 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
The anti-inflammatory effects of the plant protease inhibitor BbCI (Bauhinia bauhinioides cruzipain inhibitor), which blocks elastase, cathepsin G, and L, and proteinase 3 has been demonstrated. Here, we investigated the recombinant rBbCI-His((6)) (containing a histidine tail) in an experimental venous thrombosis model of vena cava (VC) ligature in rats, comparing to heparin. We evaluate the effects of the inhibitors (native or recombinant) or heparin on the activated partial thromboplastin time (aPTT) and prothrombin time (PT) in human and rat plasmas. The rats undergoing treatment received a saline solution or increasing concentrations of rBbCI-His((6)), heparin, or a mixture of both. After 4 h of ligature VC, thrombus, if present was removed and weighed. aPTT, PT, and cytokines were measured in blood collected by cardiac puncture. aPTT, PT, and bleeding time (BT) were also measured at the time of VC (vena cava) ligature. rBbCI-His((6)) (0.45 or 1.40 mg/kg) does not alter aPTT, PT or BT. No differences in coagulation parameters were detected in rBbCI-His((6)) treated rats at the time of VC ligature or when the thrombus was removed. There was a significant decrease in the weight of thrombus in the animals of the groups treated with the rBbCI-His((6)) (1.40 mg/kg), with the rBbCI-His((6)) mixture (1.40 mg/kg)+heparin (50 IU/kg) and heparin (100 IU/kg) in relation to control group (saline). The growth-related oncogene/keratinocyte chemoattractant (GRO/KC) serum levels in rats treated with rBbCI-His((6)) (1.40 mg/kg) or heparin (200 IU/kg) were reduced. In the experimental model used, rBbCI-His((6)) alone had an antithrombotic effect, not altering blood clotting or bleeding time. (AU) | |
| FAPESP's process: | 17/07972-9 - Development of lead agents for prophylaxis and treatment of cardiovascular diseases |
| Grantee: | Maria Luiza Vilela Oliva |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 17/06630-7 - Fragments derived from the structure of protease inhibitors with selectivity for inhibition of mammalian and microorganism enzymes and its role as an anti-inflammatory, antimicrobial, antithrombotic and anti- tumor agent: mechanism of action |
| Grantee: | Maria Luiza Vilela Oliva |
| Support Opportunities: | Research Projects - Thematic Grants |